Agenus vs Alector
AGEN and ALEC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AGEN and ALEC compare
Agenus and Alector are about the same size, with market caps of $309M and $284M.
Alector grew revenue faster over the last twelve months (151% versus 25.4% for Agenus).
Alector scores higher on the StockData Score (12 against 3 for Agenus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AGEN | ALEC |
|---|---|---|
| Size and price | ||
| Market cap | $309M | $284M |
| Share price | $6.87 | $2.54 |
| Change, 1 year | 60.9% | 89.6% |
| Change, 5 years | −90.2% | −88.1% |
| Beta (5Y) | 2.03 | 1.50 |
| Employees | 81 | 103 |
| StockData Score | ||
| Total score | 3 | 12 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 0 | 3 (better) |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 7.3× |
| P/S | 2.3× | 1.6× (better) |
| P/B | – | 2.4× |
| EV/EBITDA | 4.5× | 3.7× (better) |
| FCF yield | −33.6% (better) | −52.9% |
| Fair value | – | $8.10 |
| Margin of safety | – | 68.6% |
| Growth | ||
| Revenue growth (TTM) | 25.4% | 151% (better) |
| Revenue growth, 5Y average | 5.3% (better) | −0.05% |
| Profitability | ||
| Gross margin | 100% | – |
| Operating margin | 38.9% (better) | 20.2% |
| Net margin | – | 23.9% |
| FCF margin | −77.5% (better) | −86.5% |
| Return on equity | – | 47.5% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Net debt / EBITDA | −1.05 | −3.53 |
| Interest coverage | 0.9× | – |
| Current ratio | 0.73 | 4.10 (better) |
| Altman Z-score | −10.71 | −1.55 (better) |
| Piotroski F-score | – | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 31.7% | 85.8% |
| Held by insiders | 6.6% | 9.6% |
| Insider net buying, 12 months | – | −$1.0M |
| Short interest, % of float | 18.1% | 8.3% |
Go deeper
- AGEN stock overview
- AGEN income statement
- AGEN valuation and score
- ALEC stock overview
- ALEC income statement
- ALEC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.